What is Bio Link?
Bio Link International Inc. is a key player in the biomedical industry, focusing on the development and provision of innovative solutions for diagnostic manufacturing and scientific research. The company's product portfolio includes a variety of recombinant antigens essential for detecting diseases such as HIV, HCV, and Syphilis. These high-quality antigens are engineered for optimal performance in diverse testing methodologies, including EIA, ELISA, and RIPA tests, ensuring both sensitivity and specificity. Bio Link is dedicated to supporting the global research community by offering these critical components at competitive price points, thereby aiding in the advancement of disease research and public health initiatives.
How much funding has Bio Link raised?
Bio Link has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Bio Link
PPP
Public-Private Partnership
What's next for Bio Link?
With the recent influx of capital, Bio Link is poised for accelerated growth and expanded market penetration. The 'large-scale late-stage funding' context suggests a strategic focus on scaling operations, enhancing research and development capabilities, and potentially exploring new therapeutic areas or diagnostic platforms. This investment will likely empower Bio Link to further solidify its standing as a leading provider of biomedical solutions, driving innovation in disease detection and contributing to the fight against serious global health challenges.
See full Bio Link company page
